Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 (Businesswire) - Feb 18, 2025 - "The event will feature Aparna Goel, MD, a general transplant and hepatologist at Stanford University, who will discuss the burden of autoimmune hepatitis (AIH) on patients, current treatments and unmet needs, and expectations for how the treatment landscape will evolve in coming years. Zung To, SVP of Clinical Development, will also provide an overview of the PORTOLA Phase 2a clinical trial of zetomipzomib in patients with AIH. Kezar has completed enrollment of PORTOLA and plans to report topline data in the first half of 2025. Rachel Peterson, MD, Head of Clinical Immunology, will provide a safety update from the PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active LN, which was discontinued and unblinded in October 2024."
Clinical • P2 data • Autoimmune Hepatitis • Lupus Nephritis
|